CoChat

The effect of obesity pharmacotherapy on body composition, including muscle mass

Argyrakopoulou, Georgia, Gitsi, Evdoxia, Konstantinidou, Sofia K., Kokkinos, Alexander · 2025 · International Journal of Obesity

The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.

Abstract

Obesity pharmacotherapy represents a promising approach to treating obesity and may provide benefits beyond weight loss alone. Maintaining or even increasing muscle mass during weight loss is important to overall health, metabolic function and weight loss maintenance. Drugs such as liraglutide, semaglutide, tirzepatide, and naltrexone/bupropion have shown significant weight loss effects, and emerging evidence suggests they may also have effects on body composition, particularly a positive influence on muscle mass. However, further research is needed to fully understand the mechanism of action of these drugs and their effects on muscle mass. Clinicians should consider these factors when developing an obesity treatment plan for an individual patient.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41366-024-01533-3

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 67 references

Research works printed but not linked: 2

  1. Konwar M, Bose D, Jaiswal SK, Maurya MK, Ravi R. Efficacy and safety of liraglutide 3.0 mg in patients with overweight and obese with or without diabetes: a systematic review and meta-analysis. Int J Clin Pr. 2022;2022:1201977.
  2. Keskin L, Yaprak B. Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. Eur Rev Med Pharm Sci. 2022;26:6813–20.

Cited by

See all 32

Metadata

Authors
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A.
Affiliations
  • Athens Medical Center (GR)
  • National and Kapodistrian University of Athens (GR)
Corresponding author
Argyrakopoulou, Georgia
Venue
International Journal of Obesity
Published
2024-05-14
Volume
49
Issue
3
Pages
381-387
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W4396904658
Cited by
28
References
68
Citations by year
2026: 11 · 2025: 15 · 2024: 2
FWCI
1.75
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Journal of Obesity (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity pharmacotherapy, body composition, muscle mass, weight loss, liraglutide, semaglutide, tirzepatide, naltrexone/bupropion, weight loss maintenance, GLP-1 receptor agonists, appetite suppressants
MeSH terms
Liraglutide, Body Composition, Humans, Naltrexone, Obesity, Weight Loss, Muscle, Skeletal, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effect of obesity pharmacotherapy on body composition, including muscle mass. https://app.cochat.ai/papers/10.1038/s41366-024-01533-3
The paper
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025). The effect of obesity pharmacotherapy on body composition, including muscle mass. International Journal of Obesity. https://doi.org/10.1038/s41366-024-01533-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.